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Introduction: Methods of predicting malignant behavior of pheochromocytomas (PCCs) or 
paragangliomas (PGLs) are needed. However, there are few reliable histopathologic criteria 
to predict malignant behavior in PCC/PGLs. Recent genomic analysis of The Cancer Genome 
Atlas (TCGA) and European Molecular Biology Laboratory-European Bioinformatics 
Institute (EMBL-EBI) has provided genetic information enabling more accurate 
differentiation of disease entities. TCGA and EMBL-EBI could be utilized for the genetic 
analysis of malignant PCC/PGLs. Therefore, the objective of this study was to determine 
genomic expression differences and mutational differences of malignant PCC/PGL using data 
from TCGA and EMBL-EBI. 
Methods: TCGA had data of multigenomic analysis for 184 PCC/PGL samples while 
EBML-EBI had data for 202 PCC/PGL samples. Clinical information, mutation status, and 
mRNA expression dataset were downloaded from TCGA and EMBL-EBI. Following 
inclusion/exclusion criteria, 59 of 184 PCC/PGL samples in TCGA and 171 of 202 PCC/PGL 
samples in EMBL-EBI were selected. Of 59 samples in TCGA, 12 were malignant and 47 
were benign. Of 171 samples in EMBL-EBI, 19 were malignant and 152 were benign. Data 
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of mRNA expression and mutations were compared between these two groups. 
Results: Thirty up/down-regulated pathways in malignant PCC/PGLs were related to cancer 
signaling, metabolic alteration, prominent mitosis, and junctional dissociation. Twenty-one 
up-regulated genes and 11 down-regulated genes were significantly enriched in functional 
annotation pathways. Malignancy was more often in germline mutations of SDHB or VHL. 
Four candidate mutational genes (ATRX, SETD2, MUC16, and PAX1) were proposed as genes 
susceptible to malignancy. Overall survival rates were significantly correlated with the 
presence or absence of these somatic mutations. 
Conclusions: TCGA and EMBL-EBI showed differences in mRNA expression and mutations 
between malignant and benign PCC/PGLs. Improved recognition of prognostic factors can 
help us achieve proper diagnosis and provide appropriate treatment for PCC/PGLs. 
---------------------------------------------------------------------------------------------------------------- 
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Pheochromocytomas (PCCs) are catecholamine-producing neuroendocrine neoplasms 
originating from adrenal medulla [1]. Paragangliomas (PGLs) are catecholamine-secreting 
neuroendocrine neoplasms originating from extra-adrenal chromaffin tissues of sympathetic 
ganglia. Only 15–20% of PCC/PGLs arise from extra-adrenal chromaffin tissues whereas 80–
85% of PCC/PGLs develop from adrenal medulla. Annual incidence of PCC/PGLs is 
between 2 and 8 per million. The prevalence of PCC/PGLs in the population is 1:6,500 to 
1:2,500, respectively [2, 3]. These neoplasms present with headache, diaphoresis, tachycardia, 
hypertension, and anxiety [4]. The symptoms are due to the release of catecholamines. 
Diagnostic tests for PCC/PGLs include biochemical evaluation, imaging, and 
histopathology, in addition to genetic testing [5-7]. Germline mutations have been found in 
20-41% cases of PCC/PGLs [3]. Commercial panel tests include 10 gene mutations: MAX, 
MEN1, NF1, RET, SDHAF2, SDHB, SDHC, SDHD, TMEM127, and VHL. For management 
of patients with PCC/PGLs, physicians can consider treatments such as medical management, 
surgery, targeted radiation therapy of 131I-MIBG, chemotherapy, embolization, cryoablation, 
radiofrequency ablation, and targeted molecular therapy [8]. Since there is no curative 
management for malignant PCC/PGLs, managements usually focus on vigilant monitoring of 
metastasis in malignant PCC/PGLs. 
Considering the rule of 10s, 10% of PCC/PGLs are considered malignant [9, 10]. 
However, the malignancy rate certainly exceeds 10% in patients with extra-adrenal disease 
[11]. According to one study, 5% of adrenal-based PCCs and 33% of extra-adrenal PGLs are 
malignant [1]. Malignant PCC/PGLs show 5-year survival rates of around 50% [12, 13]. 
Their long-term survival has not been improved over the last two decades [14]. The exact 
prevalence of malignant PCC/PGLs is difficult to verify because these neoplasms can 
metastasize after resection of a mass regarded as benign. 
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Histologic analysis alone cannot predict the malignant or benign behavior of PCC/PGLs 
[15]. According to the 8th edition of the American Joint Committee on Cancer (AJCC) 
staging system, the distinctive feature of malignant PCC/PGLs is only distant metastasis. 
Therefore, their diagnostic limitations are impeding therapeutic planning. Proper diagnosis is 
directly linked to proper management and follow-up according to disease prognosis. 
Institutions have strived to define molecular markers for malignant PCC/PGLs [16, 17]. 
Efforts are ongoing to identify solid predictors of malignancy [18, 19]. 
In patients with PCC/PGLs, genetic counseling is commonly recommended owing to the 
risk of the disease itself and the importance of hereditary factors in the development of the 
disease [20-22]. Molecular diagnosis is intrinsically more essential than microscopic 
diagnosis. In the near future, genotype will be one of objective aspects used to stratify 
patients with PCC/PGLs and determine a therapeutic approach. 
Currently, molecular characterization data from The Cancer Genome Atlas (TCGA) and 
European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI) are 
available to the public [23-25]. These public datasets describe tumors including their genomic 
sequence, mutation, DNA methylation, copy-number variation, mRNA expression, 
microRNA expression, reverse phase protein array, and clinical information. TCGA and 
EMBL-EBI could be utilized for genetic analysis of malignant PCC/PGLs.  
The aim of the present study was to investigate genomic and mutational differences of 








Materials and Methods 
Study design 
Accessible data from TCGA and EMBL-EBI were obtained to compare malignant and benign 
PCC/PGLs. TCGA had multigenomic analysis data of 184 PCC/PGL samples. Initial 
pathologic diagnosis was made from 1988 to 2013. Clinical information, mutation status, and 
gene expression dataset (20,531 genes) of RNA-sequencing mRNA Fragments Per Kilobase 
Million (FPKM) were downloaded from TCGA. The dataset was integrated into a table. Only 
samples with TCGA type code 01 (primary solid tumor) were included (Figure 1). Two 
samples with type code 05 from additional primary sites and 1 sample with type code 06 from 
a metastatic site were excluded. Benign samples were included only if the follow-up was 
more than two years. However, malignant samples were included even if they were 
metastasized within two years. Aggressive samples with local invasion or metastatic lymph 
nodes were excluded due to uncertain behavior. 59 samples met the inclusion criteria. Among 
the 59 PCC/PGL samples, 12 were malignant and 47 were benign. Clinical characteristics, 
mutations, and mRNA expression were reorganized according to behavior and compared to 
each other. EMBL-EBI had multi-omics analysis data of 202 PCC/PGL samples from the 
French ‘Cortico et Médullosurrénale: les Tumeurs Endocrines’ (COMETE) Network. Cases 
were recruited from 1993 to 2008. Clinical information, mutation status, and expression 
dataset (39,534 probes) of RNA-sequencing mRNA transcripts were downloaded from 
EMBL-EBI. Only primary tumor samples were included. The selection criteria excluded the 
following: 1) 13 samples without available data, 2) 7 duplicated samples from same sources, 
3) 1 sample from psoas muscle, 4) 4 samples from lymph nodes, and 5) 4 double primary 
samples with both PCC and PGL (Figure 2). Even in eligible samples, 2 samples were further 
excluded because they were not labeled as malignant or benign. A total of 171 samples had 
accessible genomic data and corresponding clinical information. Among the 171 samples, 19 
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were malignant whereas 152 were benign. Clinical characteristics, mutations, and mRNA 
expression were reorganized according to behavior and compared to each other. For 
interpretation of gene expression, differentially expressed genes (DEGs) were extracted from 
TCGA and EMBL-EBI. Commonly enriched genes were searched by means of functional 
annotation pathway analysis. TCGA opened whole-exome sequencing somatic mutations. 
EMBL-EBI disclosed targeted Sanger sequencing somatic mutations although whole-exome 
sequencing was performed only for 31 pairs. Therefore, pivotal somatic mutations for 
malignancy were queried from TCGA and those mutations were cross-checked in EMBL-EBI. 
The information on germline mutations was more restricted in TCGA and EMBL-EBI. All 



















Figure 1. Flow diagram showing the process of enrollment in TCGA. PCC 















Figure 2. Flow diagram showing the process of enrollment in EMBL-EBI. PCC 

















Metastasis was defined as the appearance of chromaffin tissues at non-chromaffin sites 
distant from the primary tumor. Malignant or benign behavior was used to describe metastasis 
or no metastasis, respectively. In TCGA, 12 PCC/PGL samples considered as malignant were 
acquired from patients with metastasis. In EMBL-EBI, 19 PCC/PGL samples were labeled as 
malignant. Zero value was filtered for the analysis of mRNA. To identify DEGs, false 
discovery rate (FDR) <0.05 and log2 fold change (FC) ≥1.5 were set as the thresholds. 
Functional enrichment of genes was analyzed based on Gene Ontology. Kyoto Encyclopedia 
of Genes and Genomes (KEGG) was used as reference pathway database. 
 
Statistics 
Malignant and benign PCC/PGL groups were compared using Chi-square test or Fisher’s 
exact test for categorical data and Student’s t test or Mann–Whitney U test for continuous 
data without normal distribution. Overall survival rates were estimated using Kaplan–Meier 
analysis, including log-rank test. Overall survival intervals were expressed as days from the 
date of surgery to the date of the last follow-up. In two-tailed tests, a p value of less than 0.05 
was considered statistical significant. Statistical analysis was performed in R 3.4.1 (R 
Foundation for Statistical Computing, Vienna, Austria) and GSEA 2.1.0 (Broad Institute, 











A total of 59 patients with PCC/PGLs from TCGA were included in the current study. Among 
these patients, 12 with metastasis were assigned into the malignant PCC/PGL group. In the 
malignant PCC/PGL group, 9 (75.0%) patients showed progressive disease in response to 
treatment while only one (8.3%) patient experienced complete remission (Table 1). No 
demographic difference was found between malignant and benign PCC/PGLs (Table 2). The 
proportion of paraganglioma was significantly (p=0.010) higher in malignant PCC/PGLs. 
Dopamine secretion was more frequent in malignant PCC/PGLs whereas metanephrine 
secretion was only found in benign PCC/PGLs (Table 3). The size was also significantly 
greater in malignant PCC/PGLs (p<0.001). Their mean follow-up periods were 2423.5 ± 
















Table 1 Treatment responses in 12 PCC/PGL samples with malignant behavior in TCGA. 
PCC pheochromocytoma, PGL paraganglioma 
Treatment response Number of samples (n=12) 
Complete remission 1 
Partial remission 1 
Stable disease 1 





















Table 2 Comparison of identified characteristics between malignant and benign PCC/PGLs 
from TCGA. PCC pheochromocytoma, PGL paraganglioma 
Characteristic Malignant (n=12) Benign (n=47) p value 
Age (years), mean ± SD 43.1 ± 13.9 43.4 ± 13.3 0.903 
Gender, n (%)  12 47 
 Male 7 (58.3) 24 (51.1) 0.752 
Female 5 (41.7) 23 (48.9)   
Race, n (%) 12 46 0.455 
White 11 (91.7) 36 (78.2)   
African American 1 (8.3) 5 (10.9)   
Asia 0 (0) 5 (10.9)   
Laterality, n (%) 6 41 0.749 
Right 2 (33.3) 19 (46.4)   
Left 4 (66.7) 21 (51.2)   
Bilaterality 0 (0) 1 (2.4)   
Diagnosis, n (%)  12 47 0.010 
PCC 6 (50.0) 41 (87.2)   
PGL 6 (50.0) 6 (12.8)   
Size (mm), mean ± SD 81.5 ± 27.6 44.1 ± 14.3 <0.001 















Table 3 Catecholamine secretion features between malignant and benign PCC/PGLs from 
TCGA. PCC pheochromocytoma, PGL paraganglioma 
Characteristic Malignant (n=9) Benign (n=40) p value 
Biochemical testing 
   Normetanephrine  6 34 0.336 
Norepinephrine 5 24 1.000 
Epinephrine 1 15 0.238 
Metanephrine 0 21 0.006 
Methoxytyramine 1 0 0.184 





















A total of 171 patients with PCC/PGLs from EMBL-EBI were included for cross-
validation. No age or gender difference was found between malignant and benign PCC/PGLs 
(Table 4). The proportion of paraganglioma was significantly higher in malignant PCC/PGLs 
(p<0.001). The size was also significantly greater in malignant PCC/PGLs (p<0.004). A total 
of 189 samples had information of tumor size, including 48 samples from TCGA and 141 
samples from EMBL-EBI. From the 189 samples of TCGA and EMBL-EBI, the optimal cut-
off value was calculated to identify malignancy. According to ROC curves, the size of 54.5 
mm showed the highest accuracy (AUC=0.778, sensitivity=66.7%, specificity=61.6%, 



















Table 4 Comparison of identified characteristics between malignant and benign PCC/PGLs 
from EMBL-EBI. PCC pheochromocytoma, PGL paraganglioma 
Characteristic Malignant (n=19) Benign (n=152) p value 
Age (years), mean ± SD 36.4 ± 14.1 43.2 ± 16.4 0.079 
Gender, n (%)  19 152   
Male 9 (47.4) 59 (38.8) 0.780 
Female 10 (52.6) 93 (61.2)   
Diagnosis, n (%)  19 152 <0.001 
PCC 9 (47.4) 136 (89.5)   
PGL 10 (52.6) 16 (10.5)   




















Figure 3. According to ROC curves, the size of 54.5 mm showed the highest accuracy in 
TCGA and EMBL-EBI (AUC=0.778, sensitivity=66.7%, specificity=61.6%, p<0.001). ROC 















In TCGA, 6,056 out of 20,531 genes were excluded because they had zero value in at least 
one sample. By comparative analysis of 14,474 genes, 367 up-regulated genes were identified 
while 282 genes were down-regulated. A total of 39,534 probes were used in EBML-EBI. 
Results showed that 558 probes were up-regulated while 1,132 probes were down-regulated. 
In both data, quality control was performed for each gene or probe. Distribution of expression 
level was examined in various ways. Hierarchical clustering analysis was performed by 
Euclidean distance and complete linkage (Figure 4). Gene enrichment was identified by 
functional annotation analysis (Figure 5). Commonly enriched pathways in malignant 
PCC/PGLs were linked to cancer signaling, metabolic alteration, prominent mitosis, and 
junctional dissociation (Table 5). Thirty up/down-regulated pathways harbored up-regulated 
genes such as BIRC5, BRIP1, BUB1, CCNA2, CCNB1, CDK1, DIAPH3, ELOVL2, ELOVL7, 
ESPL1, FANCI, IQGAP3, ITGAV, MKI67, PMAIP1, RMI2, RRM2, RYR2, TK1, TOP2A, and 
TYMS. They also encompassed down-regulated genes such as ACOT7, CDKN1C, GPX3, 
HDAC11, HIST1H2AC, HIST1H4H, KCNJ5, NTNG1, PRKACB, and RET. These 32 common 
























Figure 4. (Continued) Hierarchical clustering analysis performed by Euclidean distance and 













Figure 5 Gene Set Enrichment Analysis showing heat map of top 50 features for each 
phenotype according to the presence of metastasis in PCC/PGLs from (a) TCGA and (b) 
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Table 5 List of 32 common genes up/down-regulated commonly in TCGA and EMBL-EBI. 
Genes Description 
BUB1 BUB1 mitotic checkpoint serine/threonine kinase 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
RYR2 ryanodine receptor 2 
TOP2A topoisomerase (DNA) II alpha 
IQGAP3 IQ motif containing GTPase activating protein 3 
DIAPH3 diaphanous related formin 3 
BIRC5 baculoviral IAP repeat containing 5 
ESPL1 extra spindle pole bodies like 1, separase 
CDK1 cyclin dependent kinase 1 
RRM2 ribonucleotide reductase regulatory subunit M2 
MKI67 marker of proliferation Ki-67 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 
TK1 thymidine kinase 1 
TYMS thymidylate synthetase 
ELOVL7 ELOVL fatty acid elongase 7 
CCNA2 cyclin A2 
ELOVL2 ELOVL fatty acid elongase 2 
RMI2 RecQ mediated genome instability 2 
FANCI Fanconi anemia complementation group I 
CCNB1 cyclin B1 
ITGAV integrin subunit alpha V 
TSC2 tuberous sclerosis 2 
ACOT7 acyl-CoA thioesterase 7 
PRKACB protein kinase cAMP-activated catalytic subunit beta 
CDKN1C cyclin dependent kinase inhibitor 1C 
GPX3 glutathione peroxidase 3 
HDAC11 histone deacetylase 11 
HIST1H4H histone cluster 1 H4 family member h 
HIST1H2AC histone cluster 1 H2A family member c 
KCNJ5 potassium voltage-gated channel subfamily J member 5 
NTNG1 netrin G1 







Table 6 List of 30 up/down-regulated pathways between malignant and benign PCC/PGLs 
from TCGA and EMBL-EBI. PCC pheochromocytoma, PGL paraganglioma, GO gene 
ontology 
GO term GO function 
Gene expression p value 
UP DOWN TCGA EMBL-EBI 
Metabolism 
fatty acid elongation ELOVL2, ELOVL7 ACOT7 0.009630 0.000198 
biosynthesis of unsaturated fatty acid ELOVL2 ACOT7 0.123855 0.002226 
glutathione metabolism RRM2 GPX3 0.003844 0.000325 
pyrimidine metabolism RRM2, TK1, TYMS 
 
<0.000001 0.022632 





cell cycle BUB1, CDK1, CCNA2, ESPL1, MKI67, TOP2A CDKN1C <0.000001 0.000009 
p53 signaling pathway CCNB1, CDK1, PMAIP1, RRM2 
 
<0.000001 <0.000001 
apoptosis BIRC5, PMAIP1 
 
0.000152 0.003513 
cellular senescence CCNA2, CCNB1, CDK1 TSC2 <0.000001 <0.000001 





PRKACB 0.002898 0.000003 
gap junction CDK1 PRKACB 0.013933 0.000390 
Environment  
Information 
cell adhesion molecule ITGAV NTNG1 0.001482 <0.000001 
PI3-AKT signaling pathway ITGAV TSC2 0.443009 <0.000001 
mTOR signaling pathway 
 
TSC2 0.205507 0.000006 
Ca2+ signaling pathway RYR2 
 
0.000633 <0.000001 
Apelin signaling pathway RYR2 PRKACB 0.177755 <0.000001 
cAMP signaling pathway RYR2 PRKACB 0.025700 <0.000001 
MAPK signaling pathway 
 
PRKACB 0.014752 <0.000001 
RAS signaling pathway 
 
PRKACB 0.133572 <0.000001 
WNT signaling pathway 
 
PRKACB 0.046904 0.000026 
FOXO signaling pathway CCNB1 
 
0.006865 0.000093 





Fanconi anemia pathway BRIP1, FANCI, RMI2 
 
<0.000001 0.020855 





chemokine signaling pathway 
 
PRKACB 0.020752 <0.000001 
insulin secretion RYR2 PRKACB 0.012737 0.001032 
circadian entrainment RYR2 KCNJ5, PRKACB 0.000246 <0.000001 
Human  
Disease 
pathways in cancer BIRC5, ITGAV PRKACB, RET <0.000001 <0.000001 
alcoholism 
 





Based on data from TCGA, 2,632 somatic mutations were identified without considering 
frequency of mutations. Of these mutations, 1,546 (58.7 %) were missense mutations and 653 
(24.8 %) were silent mutations (Figure 6). Silent mutations were discarded for mutational 
analysis. Four mutations were found to be significantly more frequent in malignant 
PCC/PGLs. These mutations were ATRX, SETD2, MUC16, and PAX1 (Table 7). These 
genetic alterations were correlated with personal neoplasm status (Figure 7). These mutations 
were expected to affect each domain. Furthermore, these mutations were significantly 
correlated with overall survival rates (Figure 8). Kaplan-Meier curve showed the most 
significant value when patients with at least one of these mutations were compared to patients 
with none of these mutations (p<0.001) (Figure 9). Intergenic interactions of these genes 
were visualized in platforms of gene expression, copy number variation, methylation, and 
protein expression by techniques described previously (Figure 10) [26]. These genes other 
than PAX1 worked positively in the same direction. Especially, ATRX and SETD2 had 













Figure 6 Variant classification of somatic mutations without considering frequency in 59 
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Table 7 Mutations significantly more frequent in malignant PCC/PGLs of TCGA. PCC 
pheochromocytoma, PGL paraganglioma, M malignant, B benign 
Genes M w/ mutation (-) M w/ mutation (+) B w/ mutation (-) B w/ mutation (+) p value 
ATRX 9 3 46 1 0.024 
SETD2 10 2 47 0 0.039 
MUC16 9 3 47 0 0.007  























Figure 7 Genetic alteration correlated with personal neoplasm status in 59 PCC/PGL samples 
















Figure 8 Kaplan–Meier curves for 59 patients from TCGA showing the effect of mutations 


















Figure 9 Kaplan-Meier curves for 59 patients from TCGA showing the most significant value 
when patients with at least one mutation of these mutations were compared to patients with 












Figure 10 Interaction of 4 genes visualized in various platforms. Only significant intergenic 
interactions were shown (FDR ≤0.1). Green lines symbolize positive interactions. The 
thickness of green lines displays the strength of interactions. GE gene expression, CN copy 









Although mutational analysis had limitations for data from EMBL-EBI, mutational rate 
of ATRX or MUC16 was higher in the malignant group based on whole exome sequencing 
data of 31 PCC/PGLs pairs. However, data regarding SETD2 or PAX1 were unavailable. In 
targeted Sanger sequencing data of EMBL-EBI, no gene was found to be significantly 
frequent in malignant group. Analysis of all accessible data on germline mutations suggested 
significant malignant progression for SDHB mutation and potential malignancy for VHL 





















Table 8 Comparison of germline mutations between malignant and benign PCC/PGLs from 













EGLN1 0 1 1.000 N/A N/A ─ 
MAX 0 0 1.000 0 1 1.000 
NF1 0 2 1.000 0 12 0.617 
RET 0 0 1.000 0 9 0.601 
TMEM127 0 1 1.000 0 1 1.000 
VHL 0 3 1.000 3 22 0.727 
SDHB 5 3 0.0049 9 15 <0.001 
SDHD 0 1 1.000 0 3 1.000 
SDHA N/A N/A ─ 0 1 1.000 



















Currently there are few reliable histopathologic criteria to predict malignant behavior in 
PCC/PGLs. Malignant potency and outcome varies with PCC/PGL genotypes. In clinical or 
pathologic aspects of the present study, possible risk factors included dopamine secretion, 
PGLs, and greater tumor size. These observations were in general agreement with previous 
studies [13, 14, 19, 27]. Genomic expression differences and mutational differences of 
malignant PCC/PGLs were investigated using TCGA and EMBL-EBI data for predicting 
prognosis in clinical practice. Thirty up/down-regulated pathways in malignant PCC/PGLs 
were associated with cancer signaling, metabolic alteration, prominent mitosis, and junctional 
dissociation. A total of 21 up-regulated genes and 11 down-regulated genes were significantly 
enriched in functional annotation pathways. In PCC/PGLs transformed to malignant types, 
cellular or nuclear proliferation was an indispensable process and down-regulation of cellular 
junctional pathway was essential for epithelial-mesenchymal transition. In addition, 4 
candidate genes with mutations were proposed as genes susceptible to malignancy while 
germline mutations of SDHB or VHL meant possible malignant PCC/PGLs in the present 
study. MUC16 or PAX1 was not yet known in PCC/PGLs. MUC16 (alias CA125) has been 
found on the apical surface of the ectodermal epithelia, playing a role as barrier [28]. PAX1 is 
silenced by methylation. It might prohibit cell proliferation or division [29]. 
PASS and GAPP have been developed to assign malignant risk on the basis of 
histopathology [30-32]. These two risk stratification systems had several common features, 
including tumor necrosis, high cellularity, large nest, and vascular or capsular invasion. These 
recurrent themes might carry some implied validity. However, these systems are limited by 
their intrinsic problems or the absence of consistent validation [30, 32]. 
In one intuitive study, 58 pheochromocytoma samples have bene analyzed in order to 
separate malignant samples [33]. Thirteen samples were classified as malignant because they 
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showed lymph node or distant metastasis. Genome-wide expression was profiled and 10 
genes among 109 DEGs were selected [33]. The current study had a similar focus to that 
study. However, the present study was designed following the awareness of challenging 
problems written in the 8th edition of the AJCC staging system. Malignant tumors may not be 
associated with local invasion or locoregional lymph node metastases. Therefore, the stricter 
definition of malignancy was applied for classifying patients with PCC/PGLs. Data from two 
public databases were used for cross-validation. Even in functionally enriched pathways, 
each cascade was investigated for common genes working in the same direction. Thirty 
functional pathways were presumably altered to malignancy. There were 21 up-regulated and 
11 down-regulated genes. They could be used as part of gene set for potential classifier 
sooner or later. 
Accumulated biological information helped us produce current results. These genes were 
cross-validated. In other studies, tumorigenesis of PCC/PGLs has been explained by 
alteration of the following three representative molecular pathways [18, 21, 23, 34, 35]: 1) 
pseudohypoxia and aberrant VEGF signaling; 2) kinase signaling such as PI3 kinase/AKT, 
RAS/RAF/ERK, and mTORC1/p70S6K; and 3) WNT signaling. In the present study, DEGs 
were enriched in 30 presumptive pathways that were closely interactive with the three known 
molecular pathways mentioned above. 
It is well-known that malignant transformation is associated with genetic aberrations. In 
sporadic PCC/PGLs, up to 24% of PCC/PGLs have genetic predisposition [1, 3, 19, 36]. 
Many previous studies have investigated germline mutations in susceptible genes and 
identified germline genes such as EPAS1, FH, MAX, MDH2, NF1, RET, SDHA, SDHAF2, 
SDHAF2, SDHB, SDHC, SDHD, TMEM127, and VHL [10, 15, 21, 34, 37-39]. In the current 
study, somatic mutations from TCGA were processed. According to molecular pathways, 
percentage of germline mutation is different from that of somatic mutation in terms of their 
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contribution to PCC/PGL tumorigenesis [18]. However, somatic mutations can make 
equivalent contribution to PCC/PGL tumorigenesis [25, 40]. Burnichon et al. have identified 
somatic mutations in VHL and RET genes [25]. Somatic mutations of NF1 and MAX have 
also been depicted by Castro-Vega et al. [24]. In a previous preview, genetic diversity has 
been introduced in aspects of germline/mosaic/somatic mutation by the timing of mutation 
acquisition from germ cell to adulthood [40]. Somatic mutation arises only in ATRX, CSDE1, 
FGFR1, HRAS, IDH1, MAML3, and SETD2. On the other hand, germline mutation occurs 
only in EGLN1, FH, MDH2, SDHAF2, SDH (A, B C, D), and TMEM127 [40]. The present 
study in close agreement with the preview, proposing 4 candidate mutations as genes 
susceptible to malignancy. 
To the best of our knowledge, this study is the first integrative analysis of TCGA and 
EMBL-EBI for malignant PCC/PGLs defined in the 8th edition of the AJCC staging system. 
We identified potential pathways leading to malignant transformation of PCC/PGLs and 
mutations frequent in malignant PCC/PGLs. Specific genes in tumors with metastasis are 
candidate markers that might be useful for screening and monitoring which can help us 
decide the extent or radicality of surgery and additional therapies. Novel molecular 
therapeutics can be considered following results of the current study. 
The present study has a few limitations. First, thorough analysis of microRNA, DNA 
methylation, copy-number variation, and protein expression should be followed to ascertain 
the complete signature of malignant PCC/PGLs. Second, the duration of follow-up was 
relatively short. A longer monitoring time might be preferable because the clinical course of 
PCC/PGLs is unpredictable. Third, as a usual limitation of big data analysis, the present study 






Data from TCGA and EMBL-EBI showed differences in mRNA expression and mutations 
between malignant and benign PCC/PGLs. Results from our analyses will facilitate 
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서론: 갈색세포종과 부신경절종의 악성 여부를 예측할 방법이 필요하다. 하지만 
악성 갈색세포종과 부신경절종을 가려낼 믿을 만한 조직병리학적 기준은 
부족하다. 최근 공용 빅 데이터인 The Cancer Genome Atlas (TCGA)와 European 
Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI)의 
등장은 질병에 대해 보다 정확히 이해할 수 있는 유전체 정보를 제공한다. 악성 
갈색세포종과 부신경절종의 유전체 분석에도 이 TCGA와 EMBL-EBI를 활용할 수 
있다. 이 연구에서는 TCGA와 EMBL-EBI 데이터를 이용하여 악성 갈색세포종과 
부신경절종의 mRNA 발현 및 돌연변이의 특징을 규명하고자 한다. 
방법: TCGA와 EMBL-EBI는 각각 184개와 202개의 갈색세포종과 부신경절종 검체에 
대해 유전체 분석 데이터를 가지고 있다. 이에 TCGA와 EBML-EBI의 임상 정보, 
돌연변이, mRNA 발현 정보를 악성 갈색세포종과 부신경절종 분석에 활용하였다. 
포함/제외 기준을 따라 TCGA에서는 59개의 검체가, EMBL-EBI에서는 171개의 
검체가 연구에 포함되었다. 59개의 TCGA 검체 중에서 12개는 악성이었으며 
47개는 양성이었다. 171개의 EMBL-EBI 검체 중에서는 19개가 악성이었으며 
152개는 양성이었다. mRNA 발현과 돌연변이를 이 두 그룹에서 비교하였다. 
결과: 악성 갈색세포종과 부신경절종은 30개의 세포 경로에서 의미있는 변화가 
관찰되었으며, 이는 암 신호전달경로, 대사변화, 세포분열, 접합해리와 연관되어 
있었다. 21개의 유전자가 상향 조절되었으며 11개의 유전자가 하향 조절되었다. 
SDHB 또는 VHL의 유전자에서 생식세포 돌연변이가 생길 경우 악성 관련성이 
있었다. 또한, 악성 그룹은 ATRX, SETD2, MUC16, PAX1의 유전자에서 체세포 
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돌연변이가 빈번하게 나타났다. 이 유전자들의 돌연변이 유무는 전체 생존율과도 
유의한 상관관계가 있었다. 
결론: TCGA와 EMBL-EBI의 갈색세포종과 부신경절종 데이터는 악성 여부에 따른 
mRNA 발현과 돌연변이의 차이를 보여주었다. 갈색세포종과 부신경절종의 
유전체에 대한 발전된 이해는 올바른 진단과 적절한 치료를 제공하는 데 도움을 
줄 수 있다. 
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